FI4244208T3 - Magl:n estäjä - Google Patents

Magl:n estäjä Download PDF

Info

Publication number
FI4244208T3
FI4244208T3 FIEP21811018.7T FI21811018T FI4244208T3 FI 4244208 T3 FI4244208 T3 FI 4244208T3 FI 21811018 T FI21811018 T FI 21811018T FI 4244208 T3 FI4244208 T3 FI 4244208T3
Authority
FI
Finland
Prior art keywords
hexafluoropropan
octane
carboxylate
azaspiro
carbamoyl
Prior art date
Application number
FIEP21811018.7T
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Inventor
john Wiener
Cheryl Grice
Daniel Buzard
Justin Cisar
Olivia Weber
Amy Allan
Nicholas Raffaele
Jeanne Moody
Michael Shaghafi
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Application granted granted Critical
Publication of FI4244208T3 publication Critical patent/FI4244208T3/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20Spiro-condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FIEP21811018.7T 2020-11-13 2021-11-12 Magl:n estäjä FI4244208T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063113662P 2020-11-13 2020-11-13
PCT/EP2021/081522 WO2022101412A1 (en) 2020-11-13 2021-11-12 A magl inhibitor

Publications (1)

Publication Number Publication Date
FI4244208T3 true FI4244208T3 (fi) 2025-06-10

Family

ID=78709459

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP21811018.7T FI4244208T3 (fi) 2020-11-13 2021-11-12 Magl:n estäjä

Country Status (33)

Country Link
US (2) US11434222B2 (https=)
EP (2) EP4244208B1 (https=)
JP (1) JP2023549051A (https=)
KR (1) KR20230107225A (https=)
CN (2) CN116547274B (https=)
AR (1) AR124057A1 (https=)
AU (1) AU2021379081A1 (https=)
CA (1) CA3196119A1 (https=)
CL (1) CL2023001339A1 (https=)
CO (1) CO2023004649A2 (https=)
CR (1) CR20230203A (https=)
DK (1) DK4244208T3 (https=)
DO (1) DOP2023000086A (https=)
ES (1) ES3025484T3 (https=)
FI (1) FI4244208T3 (https=)
GE (2) GEP20257794B (https=)
HR (1) HRP20250644T1 (https=)
HU (1) HUE071543T2 (https=)
IL (1) IL301818B1 (https=)
JO (1) JOP20230091A1 (https=)
LT (1) LT4244208T (https=)
MA (1) MA62148B1 (https=)
MX (1) MX2023005576A (https=)
PL (1) PL4244208T3 (https=)
PT (1) PT4244208T (https=)
RS (1) RS66839B1 (https=)
SA (1) SA523440403B1 (https=)
SI (1) SI4244208T1 (https=)
TW (1) TWI904281B (https=)
UA (1) UA130186C2 (https=)
UY (1) UY39516A (https=)
WO (1) WO2022101412A1 (https=)
ZA (1) ZA202304134B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
CA3242372A1 (en) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
KR20250005229A (ko) * 2022-05-04 2025-01-09 하. 룬드벡 아크티에셀스카브 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2429991A (en) * 2005-09-07 2007-03-14 Alan Barrows Water powered impulsive unit
US20110172230A1 (en) 2006-08-23 2011-07-14 Takahiro Ishii Urea compound or salt thereof
TW200902007A (en) * 2007-05-25 2009-01-16 Astrazeneca Ab Spirocyclopropyl piperidine derivatives
US20100113465A1 (en) * 2008-10-30 2010-05-06 Pfizer Inc. 7-azaspiro[3.5]nonane-7-carboxamide compounds
WO2010141817A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
FR2960875B1 (fr) * 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
WO2012047703A2 (en) * 2010-10-04 2012-04-12 Schering Corporation Cyclopropyl-spiro-piperidines useful as sodium channel blockers
PE20141702A1 (es) 2012-01-06 2014-11-19 Abide Therapeutics Inc Compuestos de carbamato y preparacion y uso de los mismos
JP6404717B2 (ja) * 2012-03-02 2018-10-17 ジェネンテック, インコーポレイテッド アミドスピロ環状アミド及びスルホンアミド誘導体
KR102179599B1 (ko) 2012-09-25 2020-11-19 에프. 호프만-라 로슈 아게 이환형 유도체
JP6647592B2 (ja) 2013-07-03 2020-02-14 ルンドベック ラ ホーヤ リサーチ センター,インク. ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用
MX2016013049A (es) 2014-04-04 2017-04-27 X-Rx Inc Inhibidores de autotaxina espirociclicos sustituidos.
JP2018513119A (ja) 2015-03-18 2018-05-24 アビデ セラピューティクス,インク. ピペラジンカルバメート、およびピペラジンカルバメートを製造ならびに使用する方法
TN2017000544A1 (en) 2015-07-31 2019-04-12 Pfizer 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
WO2017083867A1 (en) * 2015-11-12 2017-05-18 Afasci, Inc. Ion channel inhibitory compounds, pharmaceutical formulations and uses
ES2804580T3 (es) 2016-03-31 2021-02-08 Takeda Pharmaceuticals Co Compuesto heterocíclico
US10781211B2 (en) 2016-05-12 2020-09-22 Lundbeck La Jolla Research Center, Inc. Spirocycle compounds and methods of making and using same
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
CN110198944A (zh) * 2017-01-23 2019-09-03 辉瑞大药厂 作为单酰基甘油脂肪酶抑制剂的杂环螺环化合物
JP7257387B2 (ja) 2017-08-29 2023-04-13 ハー・ルンドベック・アクチエゼルスカベット スピロ環化合物並びにその作製及び使用方法
CN111032034B (zh) * 2017-08-29 2023-05-02 H.隆德贝克有限公司 螺环化合物及其制造和使用方法
KR20250005229A (ko) * 2022-05-04 2025-01-09 하. 룬드벡 아크티에셀스카브 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태

Also Published As

Publication number Publication date
IL301818A (en) 2023-06-01
US20220153721A1 (en) 2022-05-19
SI4244208T1 (sl) 2025-07-31
EP4244208A1 (en) 2023-09-20
IL301818B1 (en) 2026-02-01
CA3196119A1 (en) 2022-05-19
ES3025484T3 (en) 2025-06-09
PT4244208T (pt) 2025-05-22
GEP20257794B (en) 2025-09-10
TWI904281B (zh) 2025-11-11
CR20230203A (es) 2023-06-14
MX2023005576A (es) 2023-05-29
HUE071543T2 (hu) 2025-09-28
EP4244208B1 (en) 2025-04-02
DK4244208T3 (da) 2025-05-26
PL4244208T3 (pl) 2025-06-30
TW202229255A (zh) 2022-08-01
WO2022101412A1 (en) 2022-05-19
KR20230107225A (ko) 2023-07-14
EP4574150A2 (en) 2025-06-25
AR124057A1 (es) 2023-02-08
DOP2023000086A (es) 2023-06-30
RS66839B1 (sr) 2025-06-30
AU2021379081A1 (en) 2023-05-18
ZA202304134B (en) 2024-08-28
JP2023549051A (ja) 2023-11-22
SA523440403B1 (ar) 2024-10-10
JOP20230091A1 (ar) 2023-05-01
UY39516A (es) 2022-05-31
CN116547274A (zh) 2023-08-04
EP4574150A3 (en) 2025-08-20
LT4244208T (lt) 2025-06-10
US20240018120A1 (en) 2024-01-18
US11434222B2 (en) 2022-09-06
MA62148B1 (fr) 2025-05-30
UA130186C2 (uk) 2025-12-10
CL2023001339A1 (es) 2023-10-20
HRP20250644T1 (hr) 2025-07-18
CN116547274B (zh) 2026-02-13
CN121824488A (zh) 2026-04-10
GEAP202516246A (en) 2025-04-10
CO2023004649A2 (es) 2023-05-08

Similar Documents

Publication Publication Date Title
FI4244208T3 (fi) Magl:n estäjä
US11485745B2 (en) Amido spirocyclic amide and sulfonamide derivatives
HRP20120105T1 (hr) Aminoheterociklički spojevi
JP6985299B2 (ja) 新規(ヘテロ)アリール置換ピペリジニル誘導体、それを調製するためのプロセス、及びそれを含有する医薬組成物
AU2023356610A1 (en) Tethered heterocyclic inhibitors of kras g12c mutant proteins and uses thereof
RU2019120986A (ru) Фармацевтическая комбинация, содержащая ингибитор alk и ингибитор shp2
JP2021518395A5 (https=)
JP2023545545A (ja) 複素環スピロ化合物及び使用方法
JP2021519291A5 (https=)
RU2020133727A (ru) Ингибиторы shp2 и их применение
AR119209A1 (es) DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR
ME02514B (me) Derivati 8 -karbamoil- 2-(2,3-disupstituirani pirid-6- il)-1,2,3,4-tetrahidroizokinolina kao sredstva za izazivanje apoptoze za liječenje karcinoma i imunih i autoimunih bolesti
WO2020231977A1 (en) Compounds for treating huntington's disease
JP2021519318A5 (https=)
AU2021370660A1 (en) Heterocyclic spiro compounds and methods of use
RU2019115115A (ru) Производные пиперидина в качестве ингибиторов убиквитин-специфической протеазы 7
HRP20230086T1 (hr) Inhibitori lizin specifične demetilaze-1
JP2015504057A5 (https=)
KR20130006625A (ko) Cdk4/6의 억제제로서의 피롤로피리미딘 화합물
JP2015533822A5 (https=)
AU2013225531A1 (en) Pyridinyl and pyrimidinyl sulfoxide and sulfone derivatives
JP2016537384A5 (https=)
JP2021504380A5 (https=)
HRP20160649T1 (hr) Novi derivati tienopirimidina, postupci za njihovo pripremanje i njihova terapeutska uporaba
JPWO2022147246A5 (https=)